Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

Disposals of own shares

Brussels (Belgium), 9 October 2020 – 20:00 (CEST) – regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) announces that on 5 October 2020, in accordance with the vesting rules under its LTI plans, it has delivered for free a total of 896 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 5 October 2020 was € 99.50.

This press release is available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 
    

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
 


Stay up-to-date on the latest news and information from UCB